Slide 1: 3Q22 Earnings Presentation
3Q22 Earnings Presentation November 8, 2022
Slide 2: Safe Harbor
SAFE HARBOR This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial
Slide 3: 3Q '22 Financial Results
3Q ‘22 FINANCIAL RESULTS Org. Rev Adj Op Adj EPS Revenue Mix (%) & Organic Growth Highlights* Decline* -13% Margin* -440bps Growth* -35% Continuing Ops. Adjusted Revenue: $712 million; -17% y/y • Organic: -23%; M&A 11%; FX -6% • Non-COVID: +8% organic growth 39% 61% DX DAS • COVID: $54 million vs. $
Slide 4: Discovery & Analytical Solutions
DISCOVERY & ANALYTICAL SOLUTIONS 3Q22 Performance Food** • +51% Con’t Ops reported growth Life ✓ +DD organic with Pharma up +DD Sciences ✓ Reagents, imaging/detection, informatics, • Organic: +14%, M&A: 42%, FX: -5% and enterprise service each up +DD • +23% Pro Forma* growth Ind/Env $0.6B • Organic:
Slide 5: Diagnostics
DIAGNOSTICS 3Q22 Performance ✓ +HSD organic growth driven by newborn Applied Reproductive screening Genomics • -39% reported decline Health ✓ New assays, menu & geographic ImmunoDx • Organic: -33%; M&A: +1%; FX: -6% expansion, Vanadis • Non-COVID diagnostics organic revenue +5% ✓ -DD organic driven
Slide 6: Updated Financial Guidance
UPDATED FINANCIAL GUIDANCE 4Q22 Guidance 2022 Guidance** • Continuing Ops. Adj. Revenue: $730 million: -29% reported • Continuing Ops. Adj. Revenue: $3,300 million: -14% reported • Organic -23%; M&A 0%; FX -6% • Organic -18%; M&A 9%; FX -4% • Non-COVID Organic +8% • Non-COVID Organic +9% • Pro Forma
Slide 7: Innovating for a healthier world
INNOVATING for a healthier world Steve Willoughby | Senior Vice President, Investor Relations | steve.willoughby@perkinelmer.com | @PerkinElmerIR 7